english.prescrire.org

Welcome to the Prescrire in English website

Reliable, rigorously independent information on treatments and healthcare strategies,
to enable fully informed decision-making. Prescrire is financed by its subscribers.
No grants, no advertising. No shareholders, no sponsors.

In Prescrire's Spotlight

Dolutegravir + rilpivirine (Juluca°) dual therapy in HIV infection

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
In the November issue of Prescrire International - Gliptins: joint pain and exposure to NSAIDs

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
New special section: "Mediator° - the criminal trial"

09 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Gemtuzumab ozogamicin (Mylotarg°) in acute myeloid leukaemia: no proven benefits

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Fenspiride (Pneumorel°): serious adverse effects reported over two decades

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Industrial protectionism and medicines: too many damaging effects

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
The European Medicines Agency's independence is paramount: concrete alternatives to the fee-for-service system must be found

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
"Faces of Mediator", a new book published by Prescrire

1 October 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Enjoy these features, and more, in our upcoming issues

1 November 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Subscribe today for full access to top-quality content from Prescrire International

1 December 2018

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
"Top Texts of 2019", new from the editors of Prescrire International

28 August 2019

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Receive the free, monthly "Independent Drug & Healthcare Newsletter"

1 September 2018